- Conditions: Lung Cancer; Non Small Cell Lung Cancer (NSCLC); Breast Cancer; ER+ Breast Cancer
Interventions: Drug: entinostat; Drug: entinostat; Drug: Erlotinib; Drug: Erlotinib; Drug: Exemestane; Drug: Exemestane
Sponsors: Syndax Pharmaceuticals; Syndax Pharmaceuticals
Recruiting - verified May 2012 - Condition: Pulmonary Arterial Hypertension
Interventions: Drug: Anastrozole; Drug: Placebo
Sponsors: University of Pennsylvania; University of Pennsylvania
Not yet recruiting - verified February 2012 - Conditions: Hot Flashes; Breast Cancer
Interventions: Drug: solifenacin; Drug: Clonidine
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified February 2012 - Conditions: Muscle Pain; Joint Pain
Interventions: Drug: Vitamin D3; Drug: Vitamin D3
Sponsors: Park Nicollet Institute; Park Nicollet Institute; University of Minnesota - Clinical and Translational Science Institute; University of Southern California
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab; Drug: Aromatase Inhibitor; Drug: Induction Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Breast Neoplasms; Endocrine Breast Diseases; Neoplasm Metastasis
Interventions: Drug: letrozole; Drug: lapatinib; Drug: everolimus
Sponsors: University of Maryland; University of Maryland; Novartis Pharmaceuticals; GlaxoSmithKline
Not yet recruiting - verified December 2011 - Conditions: Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo; Procedure: quality-of-life assessment; Procedure: assessment of therapy complications; Procedure: magnetic resonance imaging; Other: laboratory biomarker analysis; Other: questionnaire administration
Sponsors: Ohio State University Comprehensive Cancer Center; Maryam Lustberg; Cancer and Leukemia Group B; Alliance
Recruiting - verified May 2012 - Condition: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions: Drug: MEDI-573; Drug: Aromatase Inhibitor
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012 - Condition: Breast Cancer
Intervention:
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012 - Conditions: Infertility; Breast Cancer
Intervention: Procedure: Random Peri-Areolar Fine Needle Aspiration (RPFNA)
Sponsors: University of Kansas; University of Kansas
Recruiting - verified July 2011 - Conditions: Arthralgia; Breast Cancer; Pain
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012 - Conditions: Estrogen Receptor-positive Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
Interventions: Biological: therapeutic estradiol; Drug: exemestane; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay
Sponsors: University of Arizona; University of Arizona; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: goserelin acetate; Drug: letrozole; Drug: anastrozole; Procedure: therapeutic conventional surgery; Genetic: DNA analysis; Other: immunohistochemistry staining method; Procedure: positron emission tomography; Genetic: comparative genomic hybridization; Procedure: biopsy; Other: laboratory biomarker analysis; Drug: chemotherapy
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Conditions: Breast Cancer; Metastatic Breast Cancer; HER-2 Positive Breast Cancer; ER Positive Breast Cancer
Intervention: Drug: AUY922
Sponsors: Texas Tech University Health Sciences Center; Texas Tech University Health Sciences Center
Recruiting - verified May 2012 - Conditions: Breast Cancer; Arthralgia
Interventions: Behavioral: Education and exercise intervention; Behavioral: Education and General Exercise
Sponsors: Georgetown University; Georgetown University
Recruiting - verified May 2011 - Condition: Lymphangioleiomyomatosis
Interventions: Drug: Letrozole; Drug: Placebo
Sponsors: University of Cincinnati; University of Cincinnati; Department of Defense
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: anastrozole; Drug: exemestane; Drug: fulvestrant; Drug: letrozole
Sponsors: National Cancer Institute (NCI); Washington University Siteman Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Conditions: Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer
Interventions: Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Genetic: gene expression analysis; Drug: systemic chemotherapy; Drug: tamoxifen citrate; Drug: aromatase inhibition therapy
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: BKM120; Drug: BEZ235; Drug: Letrozole; Drug: BKM120
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center
Recruiting - verified July 2011 - Condition: Idiopathic Short Stature
Interventions: Drug: Anastrozole and Letrozole; Drug: Somatropin; Drug: Aromatase inhibitor and somatropin
Sponsors: Nemours Children's Clinic; Nemours Children's Clinic; Thrasher Research Fund; Genentech; Novartis; AstraZeneca
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: entinostat; Drug: tamoxifen citrate; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified January 2011 - Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: letrozole
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Mayo Clinic
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Drug: Anastrozole; Drug: ADZ0530; Drug: Placebo; Procedure: Pharmacokinetic studies; Procedure: Definitive Surgery; Procedure: Core Biopsy; Genetic: Tumor Tissue Collection for Genetic and Molecular Studies
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center; Doris Duke Charitable Foundation
Recruiting - verified October 2011 - Condition: Healthy Males
Interventions: Drug: Acyline; Drug: Testosterone gel applied transdermally for 10 days; Drug: ketoconazole; Drug: Ketoconazole; Drug: Dutasteride; Drug: Anastrozole
Sponsors: University of Washington; University of Washington; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011 - Conditions: Ductal Carcinoma in Situ; Estrogen Receptor-positive Breast Cancer; Progesterone Receptor-positive Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Drug: letrozole; Drug: zoledronic acid; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: mass spectrometry; Procedure: bone scan; Procedure: quality-of-life assessment; Other: questionnaire administration; Other: pharmacogenomic studies; Other: high performance liquid chromatography
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012 - Condition: Advanced or Metastatic Breast Cancer
Intervention: Drug: KW-2450 in combination with lapatinib and letrozole
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified February 2012 - Conditions: Solid Tumors; Advanced Cancer
Interventions: Drug: Anastrozole; Drug: Bevacizumab; Drug: Everolimus; Drug: Sorafenib; Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012 - Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012 - Conditions: Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Drug: vorinostat; Other: laboratory biomarker analysis; Procedure: biopsy; Radiation: F-18 16 alpha-fluoroestradiol; Procedure: positron emission tomography; Drug: anastrozole; Drug: letrozole; Drug: exemestane; Genetic: gene expression analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Her2 Negative Breast Cancer Patients
Interventions: Drug: MM-121 (SAR256212) and Exemestane; Drug: Placebo and Exemestane
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Drug: goserelin acetate
Sponsors: National Cancer Institute (NCI); H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: letrozole; Drug: panobinostat; Genetic: RNA analysis; Genetic: microarray analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: XL147 (SAR245408); Drug: XL765 (SAR245409); Drug: letrozole (Femara)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012 - Condition: Breast Cancer
Intervention: Drug: letrozole
Sponsors: National Cancer Institute (NCI); National Cancer Institute (NCI); University of Arizona
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Other: History and Physical Exam; Other: Grip Strength Measurement; Behavioral: Surveys; Other: Blood Collection; Procedure: Ultrasound of Hand/Wrist
Sponsors: University of California, Los Angeles; University of California, Los Angeles
Recruiting - verified February 2012 - Conditions: Pregnancy; Unexplained Infertility
Interventions: Drug: Letrozole (aromatase inhibitor); Drug: Clomiphene Citrate; Drug: Follicle Stimulating Hormone (gonadotropin)
Sponsors: Yale University; Yale University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Penn State University; University of Colorado, Denver; University of Michigan; University of Pennsylvania; University of Texas; University of Vermont; Wayne State University
Recruiting - verified January 2012 - Conditions: Breast Cancer; Recurrent Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
Interventions: Procedure: acupuncture therapy; Procedure: sham intervention
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012 - Condition: Endometrial Carcinoma
Intervention: Drug: Letrozole
Sponsors: University of California, Davis; University of California, Davis
Recruiting - verified August 2011 - Condition: Breast Cancer
Interventions: Drug: Herceptin / Lapatinib; Drug: Letrozole
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center; Translational Breast Cancer Reserach Consortium; GlaxoSmithKline
Recruiting - verified January 2012 - Conditions: Atrophic Vaginitis; Breast Cancer
Intervention: Drug: Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: Exemestane; Drug: Docetaxel, cytoxan
Sponsors: Emory University; Emory University; Pfizer
Recruiting - verified February 2012 - Conditions: Advanced Non-small Cell Lung Cancer; Postmenopausal Women
Interventions: Drug: fulvestrant (Faslodex); Drug: anastrozole (Arimidex); Drug: Bevacizumab (Avastin); Drug: Best standard of care
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified January 2012 - Condition: Invasive Breast Cancer
Interventions: Drug: Fulvestrant; Drug: Anastrazole
Sponsors: University of Kansas; University of Kansas; AstraZeneca
Recruiting - verified October 2011 - Condition: Breast Cancer
Interventions: Genetic: microarray analysis; Genetic: polymerase chain reaction; Genetic: protein expression analysis; Other: diagnostic laboratory biomarker analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: immunologic technique
Sponsors: National Cancer Institute (NCI); Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified April 2008 - Condition: Breast Cancer
Interventions: Drug: exemestane; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Procedure: assessment of therapy complications
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: PD 0332991; Drug: letrozole; Drug: letrozole
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib + Letrozole; Drug: Letrozole
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; US Oncology Research
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: letrozole; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: biopsy; Procedure: therapeutic conventional surgery
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: Sorafenib; Drug: Letrozole
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey; Cancer Institute of New Jersey
Recruiting - verified June 2011 - Condition: Breast Cancer
Interventions: Drug: Letrozole; Drug: Placebo
Sponsors: University of Kansas; Carol Fabian, MD; Novartis; National Cancer Institute (NCI)
Recruiting - verified February 2012 - Condition: Breast Cancer
Interventions: Drug: RAD001; Drug: Fulvestrant
Sponsors: University of Kentucky; University of Kentucky; Novartis
Recruiting - verified December 2011 - Condition: Breast Cancer
Interventions: Drug: Arimidex with Faslodex; Drug: Arimidex without Faslodex
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center; AstraZeneca
Recruiting - verified January 2012 - Condition: Breast Cancer
Interventions: Drug: Letrozole; Drug: Letrozole
Sponsors: International Breast Cancer Study Group; International Breast Cancer Study Group
Recruiting - verified March 2012 - Conditions: Obesity; Oligospermia
Interventions: Drug: Anastrozole; Drug: Placebo
Sponsors: University of Utah; University of Utah
Recruiting - verified November 2011 - Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011 - Condition: Healthy Volunteers
Interventions: Drug: Testosterone; Drug: Testosterone; Drug: Anastrazole; Drug: Goserelin acetate
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institute on Aging (NIA); Solvay Pharmaceuticals; AstraZeneca
Recruiting - verified April 2012
 |
Aromatase Inhibitors Clinical Trials |
